Publications

Highlighted below are some of the key publications that have grown out of the Cancer Genomics Program.

Publications:

1. Araujo D, Wang A, Torti D, Leon A, Marsh K, McCarthy A, Berman H, Spreafico A, Hansen A, Razak A, Bedard P, Wang L, Plackmann E, Chow H, Bao H, Wu X, Pugh T, Siu LL. (2021). Applications of Circulating Tumor DNA in a Cohort of Phase I Solid Tumor Patients Treated with Immunotherapy. JNCI Cancer Spectrum. 10.1093/jncics/pkaa122.


2. Rose AAN, Armstrong SM, Hogg D, Butler MO, Saibil SD, Arteaga DP, Pimentel Muniz T, Kelly D, Ghazarian D, King I, Kamil ZS, Ross K, Spreafico A. Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy. J Immunother Cancer. 2021 Jan;9(1):e001642. doi: 10.1136/jitc-2020-001642. PMID: 33483342; PMCID: PMC7831745.


3. Xia D, Leon AJ, Cabanero M, Pugh TJ, Tsao MS, Rath P, Siu LL, Yu C, Bedard PL, Shepherd FA, Zadeh G, Chetty R, Aldape K. Minimalist approaches to cancer tissue-of-origin classification by DNA methylation. Mod Pathol. 2020 Oct;33(10):1874-1888. doi: 10.1038/s41379-020-0547-7. Epub 2020 May 15. PubMed PMID: 32415265.


4. Smyth LM, Zhou Q, Nguyen B, Yu C, Lepisto EM, Arnedos M, Hasset MJ, Lenoue-Newton ML, Blauvelt N, Dogan S, Micheel CM, Wathoo C, Horlings H, Hudecek J, Gross BE, Kundra R, Sweeney SM, Gao J, Schultz N, Zarski A, Gardos SM, Lee J, Sheffler-Collins S, Park BH, Sawyers CL, André F, Levy M, Meric-Bernstam F, Bedard PL, Iasonos A, Schrag D, Hyman DM. Characteristics and Outcome of AKT1E17K-Mutant Breast Cancer Defined through AACR Project GENIE, a Clinicogenomic Registry. Cancer Discov. 2020 Apr;10(4):526-535. doi: 10.1158/2159-8290.CD-19-1209. Epub 2020 Jan 10. PubMed PMID: 31924700; PubMed Central PMCID: PMC7125034.


5. Bedard PL, Hyman DM, Davids MS, Siu LL. Small molecules, big impact: 20 years of targeted therapy in oncology. Lancet. 2020 Mar 28;395(10229):1078-1088. doi: 10.1016/S0140-6736(20)30164-1. Review. PubMed PMID: 32222192.


6. Nikbakht H, Jessa S, Sukhai MA, Arseneault M, Zhang T, Letourneau L, Thomas M, Bourgey M, Roehrl MHA, Eveleigh R, Chen EX, Krzyzanowska M, Moore MJ, Giesler A, Yu C, Bedard PL, Kamel-Reid S, Majewski J, Siu LL, Riazalhosseini Y, Graham DM. Latency and interval therapy affect the evolution in metastatic colorectal cancer. Sci Rep. 2020 Jan 17;10(1):581. doi: 10.1038/s41598-020-57476-y. PubMed PMID: 31953485; PubMed Central PMCID: PMC6969060.


7. Taylor K, Yau HL, Chakravarthy A, Wang B, Shen SY, Ettayebi I, Ishak CA, Bedard PL, Razak AA, Hansen AR, Spreafico A, Cescon D, Butler MO, Oza AM, Lheureux S, Stjepanovic N, As BV, Boross-Harmer S, Wang L, Pugh TJ, Ohashi PS, Siu LL, De Carvalho DD. An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors. J Immunother Cancer. 2020 Aug;8(2):e000883. PMID: 32753546


8. Quevedo R, Spreafico A, Bruce J, Danesh A, El Ghamrasni S, Giesler A, Hanna Y, Have C, Li T, Yang C, Zhang T, Asa SL, Haibe-Kains B, Krzyzanowska M, Smith AC, Singh S, Siu LL, Pugh TJ. Centromeric cohesion failure involves a conserved choreography of chromosomal mis-segregations in pancreatic neuroendocrine tumor. Genome Med 12, 38 (2020). https://doi.org/10.1186/s13073-020-00730-9


9. Malone ER, Oliva M, Sabatini PJB, Stockley TL, Siu LL. Molecular profiling for precision cancer therapies. Genome Med. 2020 Jan 14;12(1):8. doi: 10.1186/s13073-019-0703-1. Review. PubMed PMID: 31937368; PubMed Central PMCID: PMC6961404.


10. Bratman SV, Yang SYC, Iafolla MAJ, Liu Z, Hansen AR, Bedard PL, Lhereyx S, Spreafico A, Abdul Razak A, Shchegrova S, Louie M, Billings P, Zimmermann B, Sethi H, Sleshin A, Torti D, Marsh K, Eagles J, Cirlano I, Hanna Y, Clouthier DL, Lien SC, Ohashi PS, Xu W, Siu LL, Pugh TJ. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. Nature Cancer 2020;1(9):873-81 doi 10.1038/s43018-020-0096-5.


11. Cescon DW, Bratman S, Chan S, Siu LL. Circulating tumor DNA and liquid biopsy in oncology. Nat Cancer 2020;1:276-90.


12. Araujo DV, Watson GA, Siu LL. The Day After COVID-19-Time to Rethink Oncology Clinical Research. JAMA Oncol. 2020 Sep 3. doi: 10.1001/jamaoncol.2020.4240. Epub ahead of print. PMID: 32880604.


13. Iafolla MAJ, Picardo S, Aung K, Hansen AR. Systematic Review and STARD Scoring of Renal Cell Carcinoma Circulating Diagnostic Biomarker Manuscripts. JNCI Cancer Spectr. 2020 Jun 8;4(5):pkaa050. doi: 10.1093/jncics/pkaa050. PMID: 33134830; PMCID: PMC7583155.


14. Quevedo R, Spreafico A, Bruce J, Danesh A, El Ghamrasni S, Giesler A, Hanna Y, Have C, Li T, Yang C, Zhang T, Asa SL, Haibe-Kains B, Krzyzanowska M, Smith AC, Singh S, Siu LL, Pugh TJ. Centromeric cohesion failure involves a conserved choreography of chromosomal mis-segregations in pancreatic neuroendocrine tumor. Genome Med 12, 38 (2020). https://doi.org/10.1186/s13073-020-00730-9


15. Loganathan SK, Schleicher K, Malik A, Quevedo R, Langille E, Teng K, Oh RH, Rathod B, Tsai R, Samavarchi-Tehrani P, Pugh TJ, Gingras AC, Schramek D. Rare driver mutations in head and neck squamous cell carcinomas converge on NOTCH signaling. Science. 2020 Mar 13;367(6483):1264-1269. doi: 10.1126/science.aax0902. PubMed PMID: 32165588.


16. Zhou S, Hawley JR, Soares F, Grillo G, Teng M, Madani Tonekaboni SA, Hua JT, Kron KJ, Mazrooei P, Ahmed M, Arlidge C, Yun HY, Livingstone J, Huang V, Yamaguchi TN, Espiritu SMG, Zhu Y, Severson TM, Murison A, Cameron S, Zwart W, van der Kwast T, Pugh TJ, Fraser M, Boutros PC, Bristow RG, He HH, Lupien M. Noncoding mutations target cis-regulatory elements of the FOXA1 plexus in prostate cancer. Nat Commun. 2020 Jan 23;11(1):441. doi: 10.1038/s41467-020-14318-9. PubMed PMID: 31974375; PubMed Central PMCID: PMC6978390.


17. Nikbakht H, Jessa S, Sukhai MA, Arseneault M, Zhang T, Letourneau L, Thomas M, Bourgey M, Roehrl MHA, Eveleigh R, Chen EX, Krzyzanowska M, Moore MJ, Giesler A, Yu C, Bedard PL, Kamel-Reid S, Majewski J, Siu LL, Riazalhosseini Y, Graham DM. Latency and interval therapy affect the evolution in metastatic colorectal cancer. Sci Rep. 2020 Jan 17;10(1):581. doi: 10.1038/s41598-020-57476-y. PMID: 31953485


18. Malone ER, Oliva M, Sabatini PJB, Stockley TL, Siu LL. Molecular profiling for precision cancer therapies. Genome Med. 2020 Jan 14;12(1):8. doi: 10.1186/s13073-019-0703-1. Review. PubMed PMID: 31937368; PubMed Central PMCID: PMC6961404


19. Smyth LM, Zhou Q, Nguyen B, Yu C, Lepisto EM, Arnedos M, Hassett MJ, Lenoue-Newton ML, Blauvelt N, Dogan S, Micheel CM, Wathoo C, Horlings H, Hudecek J, Gross BE, Kundra R, Sweeney SM, Gao J, Schultz N, Zarski A, Gardos SM, Lee J, Sheffler-Collins S, Park BH, Sawyers CL, Andre F, Levy M, Meric-Bernstam F, Bedard PL, Iasonos A, Schrag D, Hyman DM, Genie Consortium AP. Characteristics and outcome of AKT1 E17K-mutant breast cancer defined through AACR GENIE, a clinicogenomic registry. Cancer Discov. 2020 Jan 10. [Epub ahead of print].


20. Colombo I, Garg S, Danesh A, Bruce J, Shaw P, Tan Q, Quevedo R, Braunstein M, Oza AM, Pugh T, Lheureux S. Heterogeneous alteration of the ERBB3-MYC axis associated with MEK inhibitor resistance in a KRAS-mutated low-grade serous ovarian cancer patient. Cold Spring Harb Mol Case Stud. 2019 Dec;5(6). doi: 10.1101/mcs.a004341. Print 2019 Dec. PubMed PMID: 31836588; PubMed Central PMCID: PMC6913142.


21. Spence T, Stickle N, Yu C, Chow H, Feilotter H, Lo B, McCready E, Sadikovic B, Siu LL, Bedard PL, Stockley TL. Inter-laboratory proficiency testing scheme for tumour next-generation sequencing in Ontario: a pilot study. Curr Oncol. 2019 Dec 1;26(6):e717-e732.


22. Siravegna G, Mussolin B, Venesio T, Marsoni S, Seoane J, Dive C, Papadopoulos N, Kopetz S, Corcoran RB, Siu LL, Bardelli A. How liquid biopsies can change clinical practice in oncology. Ann Oncol. 2019 Oct;30(10):1580-1590. doi: 10.1093/annonc/mdz227. Epub 2019 Dec 27. Review. PubMed PMID: 31987449.


23. Iafolla MAJ, Picardo S, Aung K, Hansen AR. Systematic review and REMARK scoring of renal cell carcinoma prognostic circulating biomarker manuscripts. PLoS One. 2019 Oct 22;14(10)


24. Malone ER, Saleh RR, Yu C, Ahmed L, Pugh T, Torchia J, Bartlett J, Virtanen C, Hotte SJ, Hilton J, Welch S, Robinson A, McCready E, Lo B, Sadikovic B, Feilotter H, Hanna TP, Kamel-Reid S, Stockley TL, Siu LL, Bedard PL. OCTANE (Ontario-wide Cancer Targeted Nucleic Acid Evaluation): a platform for intraprovincial, national, and international clinical data-sharing. Curr Oncol. 2019 Oct 1;26(5):e618-e623.


25. Tsang CM, Lui VWY, Bruce JP, Pugh TJ, Lo KW. Translational genomics of nasopharyngeal cancer. Semin Cancer Biol. 2020 Apr;61:84-100. doi: 10.1016/j.semcancer.2019.09.006. Epub 2019 Sep 12. Review. PubMed PMID: 31521748.


26. Johnston MJ, Nikolic A, Ninkovic N, Guilhamon P, Cavalli FMG, Seaman S, Zemp FJ, Lee J, Abdelkareem A, Ellestad K, Murison A, Kushida MM, Coutinho FJ, Ma Y, Mungall AJ, Moore R, Marra MA, Taylor MD, Dirks PB, Pugh TJ, Morrissy S, St Croix B, Mahoney DJ, Lupien M, Gallo M. High-resolution structural genomics reveals new therapeutic vulnerabilities in glioblastoma. Genome Res. 2019 Aug;29(8):1211-1222. doi: 10.1101/gr.246520.118. Epub 2019 Jun 27. PubMed PMID: 31249064; PubMed Central PMCID: PMC6673710.


27. Barroso-Sousa R, Guo H, Srivastava P, James T, Birch W, Siu LL, Tew WP, Tolaney SM. Utilization of tumor genomics in clinical practice: an international survey among ASCO members. Future Oncol. 2019 Jul;15(21):2463-2470. doi: 10.2217/fon-2019-0010. Epub 2019 Jun 26. PubMed PMID: 31238721.


28. Tan T, Rheaume M, Wang L, Chow H, Spreafico A, Hansen AR, Razak ARA, Siu LL, Bedard PL. Referrals to a Phase I Clinic and Trial Enrollment in the Molecular Screening Era. Oncologist. 2019 Jul 1;24(7):e518-e525.


29. Rodriguez-Freixinos V, Lheureux S, Mandilaras V, Clarke B, Dhani NC, Mackay H, Butler MO, Wang L, Siu LL, Kamel-Reid S, Stockley T, Bedard PL, Oza AM. Impact of somatic molecular profiling on clinical trial outcomes in rare epithelial gynecologic cancer patients. Gynecol Oncol. 2019 May 1;153(2):304-311.


30. Araujo DV, Bratman SV, Siu LL. Designing circulating tumor DNA-based interventional clinical trials in oncology. Genome Med. 2019 Apr 19;11(1):22.


31. Sukhai MA, Misyura M, Thomas M, Garg S, Zhang T, Stickle N, Virtanen C, Bedard PL, Siu LL, Smets T, Thijs G, Van Vooren S, Kamel-Reid S, Stockley TL. Somatic Tumor Variant Filtration Strategies to Optimize Tumor-Only Molecular Profiling Using Targeted Next-Generation Sequencing Panels. J Mol Diagn. 2019 Mar;21(2):261-273. doi: 10.1016/j.jmoldx.2018.09.008. Epub 2018 Dec 19. PubMed PMID: 30576869.


32. Wells JC, Tu D, Siu LL, Shapiro JD, Jonker DJ, Karapetis C, Simes J, Liu G, Price TJ, Tebbutt NC, O'Callaghan CJ. Outcomes of Older Patients (≥ 70 Years) Treated With Targeted Therapy in Metastatic Chemorefractory Colorectal Cancer: Retrospective Analysis of NCIC CTG CO.17 and CO.20. Clin Colorectal Cancer. 2019 Mar;18(1):e140-e149. doi: 10.1016/j.clcc.2018.11.006. Epub 2018 Nov 28. PubMed PMID: 30595557.


33. Condorelli R, Mosele F, Verret B, Bachelot T, Bedard PL, Cortes J, Hyman DM, Juric D, Krop I, Bieche I, Saura C, Sotiriou C, Cardoso F, Loibl S, Andre F, Turner NC. Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann Oncol. 2019 Mar 1;30(3):365-373.


34. Mandilaras V, Garg S, Cabanero M, Tan Q, Pastrello C, Burnier J, Karakasis K, Wang L, Dhani NC, Butler MO, Bedard PL, Siu LL, Clarke B, Shaw PA, Stockley T, Jurisica I, Oza AM, Lheureux S. TP53 mutations in high grade serous ovarian cancer and impact on clinical outcomes: a comparison of next generation sequencing and bioinformatics analyses. Int J Gynecol Cancer. 2019 Jan 18.


35. Lee DD, Leão R, Komosa M, Gallo M, Zhang CH, Lipman T, Remke M, Heidari A, Nunes NM, Apolónio JD, Price AJ, De Mello RA, Dias JS, Huntsman D, Hermanns T, Wild PJ, Vanner R, Zadeh G, Karamchandani J, Das S, Taylor MD, Hawkins CE, Wasserman JD, Figueiredo A, Hamilton RJ, Minden MD, Wani K, Diplas B, Yan H, Aldape K, Akbari MR, Danesh A, Pugh TJ, Dirks PB, Castelo-Branco P, Tabori U. DNA hypermethylation within TERT promoter upregulates TERT expression in cancer. J Clin Invest. 2019 Jan 2;129(1):223-229. doi: 10.1172/JCI121303. Epub 2018 Dec 3. PubMed PMID: 30358567; PubMed Central PMCID: PMC6307937.


36. Sukhai MA, Misyura M, Thomas M, Garg S, Zhang T, Stickle N, Virtanen C, Bedard PL, Siu LL, Smets T, Thijs G, Van Vooren S, Kamel-Reid S, Stockley TL. Somatic Tumor Variant Filtration Strategies to Optimize Tumor-Only Molecular Profiling Using Targeted Next-Generation Sequencing Panels. J Mol Diagn. 2018 Dec 19. pii: S1525-1578(17)30598-6. doi: 10.1016/j.jmoldx.2018.09.008. [Epub ahead of print]. PMID: 30576869


37. Micheel CM, Sweeney SM, LeNoue-Newton ML, André F, Bedard PL, Guinney J, Meijer GA, Rollins BJ, Sawyers CL, Schultz N, Shaw KRM, Velculescu VE, Levy MA, AACR Project GENIE Consortium. American Association for Cancer Research Project Genomics Evidence Neoplasia Information Exchange: From Inception to First Data Release and Beyond-Lessons Learned and Member Institutions’ Perspectives. JCO Clin Cancer Inform. 2018 Dec;2:1-14. doi: 10.1200/CCI.17.00083. PMID: 30652542


38. Shen SY, Singhania R, Fehringer G, Chakravarthy A, Roehrl MHA, Chadwick D, Zuzarte PC, Borgida A, Wang TT, Li T, Kis O, Zhao Z, Spreafico A, Medina TDS, Wang Y, Roulois D, Ettayebi I, Chen Z, Chow S, Murphy T, Arruda A, O’Kane GM, Liu J, Mansour M, McPherson JD, O’Brien C, Leighl N, Bedard PL, Fleshner N, Liu G, Minden MD, Gallinger S, Goldenberg A, Pugh TJ, Hoffman MM, Bratman SV, Hung RJ, De Carvalho DD. Sensitive tumour detection and classification using plasma cell-free DNA methylomes. Nature. 2018 Nov 1;563(7732):579-583. doi: 10.1038/s41586-018-0703-0. Epub 2018 Nov 14. PMID: 30429608


39. Yang SYC, Lheureux S, Karakasis K, Burnier JV, Bruce JP, Clouthier DL, Danesh A, Quevedo R, Dowar M, Hanna Y, Li T, Lu L, Xu W, Clarke BA, Ohashi PS, Shaw PA, Pugh TJ, Oza AM. Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors. Genome Med. 2018 Oct 31;10(1):81. doi: 10.1186/s13073-018-0590-x. PMID: 30382883


40. Mateo J, Chakravarty D, Dienstmann R, Jezdic S, Gonzalez-Perez A, Lopez-Bigas N, Ng CKY, Bedard PL, Tortora G, Douillard JY, Van Allen EM, Schultz N, Swanton C, André F, Pusztai L. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann Oncol. 2018 Sep 1;29(9):1895-1902. doi: 10.1093/annonc/mdy263. PMID: 30137196


41. Aung KL, Bedard PL, Yu C, Boerner SL, Zuzarte PC, Ghai S, Berman HK, Serra S, Giesler A, Ahmed L, Joshua AM, Moore MJ, Oza AM, Amir E, McPherson JD, Zhang T, Sukhai MA, Stockley TL, Kamel-Reid S, Siu LL, Hansen AR. Minimally Invasive Real-Time Detection of Actionable Mutations in Patients With Metastatic Solid Tumors Using Fine-Needle and Liquid Biopsies. JCO Precision Oncology. JCO Precision Oncology 2018 :2, 1-20


42. Stjepanovic N, Stockley TL, Bedard PL, McCuaig JM, Aronson M, Holter S, Semotiuk K, Leighl NB, Jang R, Krzyzanowska MK, Oza AM, Gupta A, Elser C, Ahmed L, Wang L, Kamel-Reid S, Siu LL, Kim RH. Additional germline findings from a tumor profiling program. BMC Med Genomics. 2018 Aug 9;11(1):65. doi: 10.1186/s12920-018-0383-5. PMID: 30092803


43. Malone E and Siu LL. Precision Medicine in Head and Neck Cancer: Myth or Reality? Clin Med Insights Oncol. 2018 Jun 4;12:1179554918779581. doi: 10.1177/1179554918779581. eCollection 2018. PMID 29887732


44. Kratz J, Burkard M, O’Meara T, Pusztai L, Veitch Z, Bedard PL. Incorporating Genomics Into the Care of Patients With Advanced Breast Cancer. Am Soc Clin Oncol Educ Book. 2018 May 23(38):56-64. doi: 10.1200/EDBK_200731. PMID: 30231387


45. Korpanty GJ, Kamel-Reid S, Pintilie M, Hwang DM, Zer A, Liu G, Leighl NB, Feld R, Siu LL, Bedard PL, Tsao MS, Shepherd FA. Lung cancer in never smokers from the Princess Margaret Cancer Centre. Oncotarget. 2018 Apr 27;9(32):22559-22570. doi: 10.18632/oncotarget.25176. eCollection 2018 Apr 27. PMID: 29854298


46. Chiu JW, Krzyzanowska MK, Serra S, Knox JJ, Dhani NC, Mackay H, Hedley D, Moore M, Liu G, Burkes RL, Brezden-Masley C, Roehrl MH, Craddock KJ, Tsao MS, Zhang T, Yu C, Kamel-Reid S, Siu LL, Bedard PL, Chen EX. Molecular Profiling of Patients With Advanced Colorectal Cancer: Princess Margaret Cancer Centre Experience. Clin Colorectal Cancer. 2018 Mar 1;17(1):73-79. doi: 10.1016/j.clcc.2017.10.010. Epub 2017 Oct 23. PMID: 29128266


47. Pezo RC, Chen TW, Berman HK, Mulligan AM, Razak AA, Siu LL, Cescon DW, Amir E, Elser C, Warr DG, Sridhar SS, Yu C, Wang L, Stockley TL, Kamel-Reid S, Bedard PL. Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer. Breast Cancer Res Treat. 2018 Feb 1;168(1):159-168. doi: 10.1007/s10549-017-4580-2. Epub 2017 Nov 24. PMID: 29177603


48. Spreafico A, Oza AM, Clarke BA, Mackay HJ, Shaw P, Butler M, Dhani NC Lheureux S, Wilson MK, Welch S, Zhang T, Yu C, Stockley T, Siu LL, Kamel-Reid S, Bedard PL. Genotype-matched treatment for patients with advanced type I epithelial ovarian cancer (EOC). Gynecol Oncol. 2017 Jan 3. pii: S0090-8258(16)31620-1. doi: 10.1016/j.ygyno.2016.12.002. [Epub ahead of print] PMID: 28062115


49. The AACR Project GENIE Consortium. AACR Project GENIE: Powering Precision Medicine through an International Consortium. Cancer Discov June 26, 2017. DOI: 10.1158/2159-8290.CD-17-0151.


50. Chiu JW, Krzyzanowska MK, Serra S, Knox JJ, Dhani NC, Mackay H, Hedley D, Moore M, Liu G, Burkes RL, Brezden-Masley C, Roehrl MH, Craddock KJ, Tsao M-S, Zhang T, Yu C, Kamel-Reid S, Siu LL, Bedard PL, Chen EX, Molecular profiling of patients with advanced colorectal cancer: Princess Margaret Cancer Centre experience. Clinical Colorectal Cancer. 2017. doi: 10.1016/j.clcc.2017.10.010.


51. Pezo RC, Chen TW, Ber,am HK, Mulligan AM, Razak AA, Siu LL, Cescon DW, Amir E, Elser C, Warr DG, Sridhart SS, Yu C, Wang L, Stockley TL, Kamel-Reid S, Bedard PL. Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer. Breast Cancer Res Treat (2017).


52. Prawira A , Pugh TJ , Stockley TL , Siu LL. (2017). Data resources for the identification and interpretation of actionable mutations by clinicians. Annals of oncology : official journal of the European Society for Medical Oncology. 28(5): 946-957.


53. Vis DJ , Lewin J , Liao RG , Mao M , Andre F , Ward RL , Calvo F , Teh BT , Camargo AA , Knoppers BM , Sawyers CL , Wessels LFA , Lawler M , Siu LL , Voest E , Clinical Working Group of the Global Alliance for Genomics and Health. (2017). Towards a global cancer knowledge network: dissecting the current international cancer genomic sequencing landscape. Annals of oncology : official journal of the European Society for Medical Oncology. 28(5): 1145-1151.


54. Henry NL, Bedard PL, DeMichele A.(2017). Standard and Genomic Tools for Decision Support in Breast Cancer Treatment. Am Soc Clin Oncol Educ Book. 37(0): 106-115.


55. Clinical Cancer Genome Task Team of the Global Alliance for Genomics and Health, Lawler M, Haussler D, Siu LL, Haendel MA, McMurry JA, Knoppers BM, Chanock SJ, Calvo F, The BT, Walia G, Banks I, Yu PP, Staudt LM, Sawyers CL. (2017). Sharing Clinical and Genomic Data on Cancer - The Need for Global Solutions. The New England journal of medicine. 376(21): 2006-2009.


56. Cescon D, Siu LL. Cancer Clinical Trials: The Rear-View Mirror and the Crystal Ball. Cell. 2017 Feb 9;168(4):575-578. doi: 10.1016/j.cell.2017.01.027. PubMed PMID: 28187280.


57. Siu LL, Lawler M, Haussler D, Knoppers BM, Lewin J, Vis DJ, Liao RG, Andre F, Banks I, Barrett JC, Caldas C, Camargo AA, Fitzgerald RC, Mao M, Mattison JE, Pao W, Sellers WR, Sullivan P, Teh BT, Ward RL, ZenKlusen JC, Sawyers CL, Voest EE. Facilitating a culture of responsible and effective sharing of cancer genome data. Nat Med. 2016 May 5; 22(5):464-71. doi: 10.1038/nm.4089. PubMed PMID: 27149219; PubMed Central PMCID: PMC4995884.


58. Spreafico A, Oza AM, Clarke BA, Mackay HJ, Shaw P, Butler M, Dhani NC Lheureux S, Wilson MK, Welch S, Zhang T, Yu C, Stockley T, Siu LL, Kamel-Reid S, Bedard PL. Genotype-matched treatment for patients with advanced type I epithelial ovarian cancer (EOC). Gynecol Oncol. 2017 Jan 3. pii: S0090-8258(16)31620-1. doi: 10.1016/j.ygyno.2016.12.002. [Epub ahead of print] PMID: 28062115


59. Stockley TL, Oza AM, Berman HK, Leighl NB, Knox JJ, Shepherd FA, Chen EX, Krzyzanowska MK, Dhani N, Joshua AM, Tsao MS, Serra S, Clarke B, Roehrl MH, Zhang T, Sukhai MA, Califaretti N, Trinkaus M, Shaw P, van der Kwast T, Wang L, Virtanen C, Kim RH, Razak AR, Hansen AR, Yu C, Pugh TJ, Kamel-Reid S, Siu LL, Bedard PL. Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial. Genome Med. 2016 Oct 25;8(1):109. PMID: 27782854


60. Aung KL, Stockley TL, Serra S, Kamel-Reid S, Bedard PL, Siu LL. Testing ERBB2 p.L755S kinase domain mutation as a druggable target in a patient with advanced colorectal cancer. Cold Spring Harb Mol Case Stud. 2016 Sep;2(5):a001016. doi: 10.1101/mcs.a001016. PMID: 27626067


61. Day D, Bedard PL. Beta-Testing of Next-Generation DNA Sequencing for Patients With Advanced Cancers Treated at Community Hospitals. J Oncol Pract. 2016 Apr;12(4):279-81. doi: 10.1200/JOP.2015.010165. PMID: 26957640


62. Sukhai MA, Craddock KJ, Thomas M, Hansen AR, Zhang T, Siu L, Bedard P, Stockley TL, Kamel-Reid S. A classification system for clinical relevance of somatic variants identified in molecular profiling of cancer. Genet Med. 2016 Feb;18(2):128-36. doi: 10.1038/gim.2015.47. PMID: 25880439

Abstracts:

1. Saleh R, Bedard PL, Nguyen P, Malone ER, Yu C, Amir E, Earle C, Gyawali B, Hansen AR, Mittmann N, Peng Y, Pugh TJ, Razak AR, Sabatini P, Spreafico A, Stockley T, Torchia J, Williams C, Siu LL, Hanna TP. An evaluation of administrative data linkage for measurement of real-world outcomes of large clinical panel sequencing for advanced solid tumors. 2020 ASCO Annual Conference (Virtual). Chicago, Illinois, United States. J Clin Oncol 38: 2020 (suppl; abstr e19303)


2. Zhao EY, Torchia J, Fortuna A, Torti D, Yu C, Shah E, McCarthy A, Stockley T, Sabatini P, Bartlett J, Siu LL, Bedard PL, Pugh TJ. Exomes and transcriptomes to reveal actionable findings in patients with negative-targeted panel sequencing. 2020 ASCO Annual Conference (Virtual). Chicago, Illinois, United States. J Clin Oncol 38: 2020 (suppl; abstr 3562)


3. Muniz TP, Sorotsky S, Kanjanapan T, Rose AAN, Araujo DV, Fortuna A, Ghazarian DK, Kamil ZS, Pugh TJ, Mah M, Thiagarajah M, Spreafico A, Hogg D. Genomic landscape of malignant peripheral nerve sheath tumor (MPNST)-like melanoma. 2020 ASCO Annual Conference (Virtual). Chicago, Illinois, United States. J Clin Oncol 38: 2020 (suppl; abstr e22072)


4. Rose AAN, Ayodele O, Muniz T, Kelly D, Araujo DV, Malone E, Wang T, Lau G, Nouriany N, Hodgson K, Ahmed L, Shah E, Woo J, Yu C, Butler M, Shepherd FA, Bedard PL, Leighl N, Abdul Razak A, Hansen A, Saibil S, Cescon C, Siu LL, Spreafico S. Preliminary results of an investigator-initiated Phase II study: Binimetinib and Encorafenib for the treatment of Advanced solid tumors with non-V600E BRAF mutations (BEAVER). Division of Medical Oncology Research Day, University of Toronto, Toronto, ON. Jun 15, 2020. (Best Abstract Award)


5. Jiang DM, Wong B, Hansen AR, Fallah-Rad N, Sacher AG, Zhang T, Selvarajah S, Stockley T, Bedard PL, Sridhar, SS. Comprehensive Genomic Profiling (CGP) of Metastatic Castrate Sensitive Prostate Cancer (mCSPC) Reveals High Frequency of Potential Therapeutic Targets. 2020 ASCO Annual Conference (Virtual). Journal of Clinical Oncology 2020 38:6_suppl, 198-198


6. Malone ER, Spreafico S, Weinreb I, Jennings S, Carlsson L, Noori A, Wang L, Siu LL, Hansen AR. Recurrent or metastatic salivary gland tumor (MSGT) patients treated with selinexor, a first in class selective exportin-1 (XPO1) inhibitor. 2020 ASCO Annual Conference (Virtual). J Clin Oncol 38: 2020 (suppl; abstr 6586)


7. Jiang DM, Wong B, Hansen AR, Fallah-Rad N, Sacher AG, Zhang T, Selvarajah S, Stockley T, Bedard PL, Sridhar SS. Comprehensive Genomic Profiling (CGP) of Metastatic Castrate Sensitive Prostate Cancer (mCSPC) Reveals Potential Biomarkers and Therapeutic Targets. 2020 Genitourinary Cancers Symposium, Feb 13-15, 2020. San Francisco, USA.


8. Feng S, Al-Showbaki L, Krzyzanowska MK, Prince RM, Stockley T, Yu C, Bedard PL, Siu LL, Chen EX. BRCA mutations in metastatic colorectal cancer (mCRC) and response to chemotherapy. 2020 Genitourinary Cancers Symposium, Feb 13-15, 2020. San Francisco, USA.


9. Leung E, Han K, Zou J, Zhao Z, Zheng Y, Wang TT, Siu LL, Pugh TJ, Bratman SV. HPV sequencing facilitates ultrasensitive detection of HPV circulating tumor DNA [abstract]. In: Proceedings of the AACR Special Conference on Advances in Liquid Biopsies; Jan 13-16, 2020; Miami, FL. Philadelphia (PA): AACR; Clin Cancer Res 2020;26(11_Suppl):Abstract nr A45


10. Lau SCM, Soleimani S, Wong SWY, Wang BX, Pedersen S, Elkrief A, Patel D, Fares A, Jao K, Daaboul N, Hakozaki T, Bradbury PA, Liu G, Leighl NB, Tsao MS, Ohashi PS, Pugh TJ, Routy B, Shepherd FA, Sacher AG. TCR clonality and Treg frequency as predictors of outcome in stage 3 NSCLC treated with durvalumab. DOI: 10.1200/JCO.2020.38.15_suppl.3050 Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020) 3050-3050.


11. Jiang DM, Wong B, Hansen AR, Fallah-Rad N, Sacher AG, Zhang T, Selvarajah S, Stockley T, Bedard PL, Sridhar SS. Comprehensive Genomic Profiling (CGP) of Metastatic Castrate Sensitive Prostate Cancer (mCSPC) Reveals Potential Biomarkers and Therapeutic Targets. 2020 Genitourinary Cancers Symposium, Feb 13-15, 2020. San Francisco, USA.


12. Feng S, Al-Showbaki L, Krzyzanowska MK, Prince RM, Stockley T, Yu C, Bedard PL, Siu LL, Chen EX. BRCA mutations in metastatic colorectal cancer (mCRC) and response to chemotherapy. 2020 Genitourinary Cancers Symposium, Feb 13-15, 2020. San Francisco, USA.


13. Hong R, Edgar K, Song K, Steven S, Young A, Hamilton P, Arrazate A, De La Cruz C, Chan C, Pang J, Salpati L, Belvin M, Nannini M, Staben S, Friedman L, Sampath D. GDC-0077 is a selective PI3K alpha inhibitor with robust efficacy in PIK3CA mutant hormone-positive breast cancer models. 2019 San Antonio Breast Cancer Symposium (SABCS), Dec 12, 2019. San Antonio, USA.


14. Araujo DV, Wang A, Torti D, Huang J, Leon A, Marsh K, McCarthy A, Razak AA, Bedard PL, Wang L, Plackmann E, Chow H, Bao H, Wu X, Pugh TJ, Siu LL. Blood-based TMB correlates with tissue-based TMB in a multi-cancer Phase 1 IO Cohort. ESMO 2019 Congress, Sep 27-Oct 1, 2019. Barcelona, Spain.


15. Han K, Leung E, Zhao Z, Zheng Y, Huang SH, Liu FF, Waldron J, Siu LL, Pugh TJ, Bratman S. Viral Genome Sequencing for Ultrasensitive Detection of Circulating Tumor DNA. ASTRO’s 61st Annual Meeting, American Society for Radiation Oncology (ASTRO), Sept 15-18,2019. Chicago, USA.


16. Rose AAN, Armstrong SM, Hogg D, Butler M, Joshua AM, Ghazarian D, Kamel-Reid S, Al Habeeb A, Chappell MA, Ross K, Amir E, Bedard PL, Siu L, Spreafico A. The relationship between BRAF/NRAS/KIT genomic driver mutations and anti-PD1 immunotherapy responses in patients with advanced melanoma. 2019 AACR, Apr 2, 2019. Atlanta, USA.


17. Philippe L. Bedard, Amit M. Oza, Ming-Sound Tsao, Natasha B. Leighl, Frances A. Shepherd, Eric Xueyu Chen, Ian Tannock, Monika K. Krzyzanowska, Neesha C. Dhani, Blaise Clarke, Hal K. Berman, Stefano Serra, Kenneth J. Craddock, Dianne Chadwick, Tong Zhang, Mahadeo A. Sukhai, Celeste Yu, Aaron Richard Hansen, Suzanne Kamel-Reid, Lillian L. Siu. Princess Margaret Cancer Centre (PMCC) Integrated Molecular Profiling in Advanced Cancers Trial (IMPACT) using genotyping and targeted next-generation sequencing (NGS). ASCO 2013 – Oral Abstract Session, Tumor Biology.


18. Wei-Wu T. Chen, Ian F. Tannock, Hal Berman, Anna Marie Mulligan, Eitan Amir, Albiruni R.A. Razak, Celeste Yu, Suzanne Kamel-Reid, Lillian L. Siu, Philippe L. Bedard. The Princess Margaret (PM) Cancer Centre experience with molecular profiling of metastatic breast cancer (MBC) to screen for genotype-matched clinical trials. EBCC-9 – Oral Presentation, Tomorrow’s Practice Changing Abstracts.


19. Joanne W. Chiu, Philippe L. Bedard, Michael H. Roehrl, Stefano Serra, Monika K. Kryzanowska, Jennifer J. Knox, Helen Mackay, David W. Hedley, Malcolm J. Moore, Geoffrey Liu, Neesha C. Dhani, Suzanne Kamel-Reid, Emina Torlakovic, Tao Wang, Ming-Sound Tsao, Dianne Chadwick, Tong Zhang, Celeste Yu, Eric Xueyu Chen. Molecular profiling of patients (pts) with advanced colorectal cancer (CRC): Princess Margaret Cancer Centre experience ASCO GI Cancers Symposium – General Poster Session: Cancers of the Colon and Rectum.


20. Anna Spreafico, Amit M. Oza, Blaise Clarke, Helen Mackay, Patricia Shaw, Golnar Rasty, Marcus O. Butler, Neesha C. Dhani, Stephanie Lheureux, Michelle Wilson, Stephen Welch, Lillian L. Siu, Tong Zhang, Celeste Yu, Geeta D Krishna, Helen Chow, Tracy Stockley, Suzanne Kamel-Reid, Philippe L. Bedard. Genotype matched treatment for patients with advanced type I epithelial ovarian cancer (EOC). ASCO 2014 – Oral Abstract Session, Gynecologic Cancer [Merit Award and NOYCIA for Dr. A. Spreafico]


21. Donna M. Graham, Madeleine Arseneault, Mahadeo A. Sukhai, Louis Letourneau, Mehran Karimzadeh, Tong Zhang, Mariam Thomas, Michael H. A. Roehrl, Eric Xueyu Chen, Monika K Krzyzanowska, Malcolm J. Moore, Amanda Giesler, Celeste Yu, Philippe L. Bedard, Suzanne Kamel-Reid, Lillian L. Siu, Yasser Riazalhosseini. Analysis of clonal evolution of colorectal cancer. ASCO 2014 – Oral Abstract Session, Gastrointestinal (Colorectal Cancer)

Manuscripts:

1. Blanchette PS, Spreafico A, Miller FA, Chan K, Bytautas J, Kang S, Bedard PL, Eisen A, Potanina L, Holland J, Kamel-Reid S, McPherson JD, Razak AR, Siu LL. Genomic testing in cancer: Patient knowledge, attitudes, and expectations. Cancer. 2014 Jun 24. doi: 10.1002/cncr.28807. [Epub ahead of print] PubMed PMID: 24962202


2. Bedard PL, Hansen AR, Ratain MJ, Siu LL. Tumour heterogeneity in the clinic. Nature. 2013 Sep 19;501(7467):355-64. doi: 10.1038/nature12627. PubMed PMID: 24048068.


3. Sleijfer S, Bogaerts J, Siu LL. Designing transformative clinical trials in the cancer genome era. J Clin Oncol. 2013 May 20;31(15):1834-41. doi: 10.1200/JCO.2012.45.3639. Epub 2013 Apr 15. Review. PubMed PMID: 23589555


4. Hansen AR, Bedard PL. Clinical application of high-throughput genomic technologies for treatment selection in breast cancer. Breast Cancer Res. 2013;15(5):R97. PubMed PMID: 24135425; PubMed Central PMCID: PMC3979162.


5. Chen TW, Bedard PL. Personalized medicine for metastatic breast cancer. Curr Opin Oncol. 2013 Nov;25(6):615-24. doi: 10.1097/CCO.0000000000000015. Review. PubMed PMID: 24097103.


6. Tran B, Brown AM, Bedard PL, Winquist E, Goss GD, Hotte SJ, Welch SA, Hirte HW, Zhang T, Stein LD, Ferretti V, Watt S, Jiao W, Ng K, Ghai S, Shaw P, Petrocelli T, Hudson TJ, Neel BG, Onetto N, Siu LL, McPherson JD, Kamel-Reid S, Dancey JE. Feasibility of real time next generation sequencing of cancer genes linked to drug response: results from a clinical trial. Int J Cancer. 2013 Apr 1;132(7):1547-55. doi: 10.1002/ijc.27817. Epub 2012 Oct 11. PubMed PMID: 22948899.


7. Tran B, Dancey JE, Kamel-Reid S, McPherson JD, Bedard PL, Brown AM, Zhang T, Shaw P, Onetto N, Stein L, Hudson TJ, Neel BG, Siu LL. Cancer genomics: technology, discovery, and translation. J Clin Oncol. 2012 Feb 20;30(6):647-60. doi: 10.1200/JCO.2011.39.2316. Epub 2012 Jan 23

Oral Presentations:

1. Bedard, PL. Genomic testing in clinical trials. Clinica Universidad de Navarra, Spain. Jul 9, 2020. Available from: https://www.doctaforum.org/2020/genomicscancer2020/


2. Bedard, PL. The importance of molecular screening programmes (tissue biopsy). European Society for Medical Oncology (ESMO) Breast Cancer Virtual Meeting, Switzerland. May 23, 2020.


3. Bedard, PL. Clinical Implications of Using Different Assays for Diagnosing Breast Cancer. Canadian Breast Cancer Symposium, Whistler, British Columbia, Canada. Jan 31, 2020.


4. Bedard, PL. Debate: Whole Genome Sequencing Should be Done for Patients with Metastatic Breast Cancer (PRO). Canadian Breast Cancer Symposium, Whistler, British Columbia, Canada. Jan 31, 2020.


5. Siu, LL. Rethinking Clinical Trials in the Era of Precision Cancer Medicine. Colorectal Cancer Cancer Virtual Conference. Oct 21, 2020.


6. Siu, LL. In Pursuit of Multi-Omic Predictive Biomarkers for Immunotherapy via Team Science Approach. Case Comprehensive Cancer Center Seminar Series (virtual). Oct 2, 2020.


7. Siu, LL. The Future of Cancer Genomics”. 3rd International Workshop on Genomic Testing in Cancer: Towards an Immune-Genomic Approach for Cancer Treatment (virtual). Jul 8-10, 2020.


8. Siu, LL. Precision Medicine. Current Concepts in Head and Neck Cancer 2020. Porto, Portugal. Feb 26-27, 2020.


9. Siu, LL. Molecular Targeted Therapy for Salivary Gland Cancer. Current Concepts in Head and Neck Cancer 2020. Porto, Portugal. Feb 26-27, 2020.


10. Siu, LL. ctDNA as Predictive Biomarkers of Response and Toxicity with Immunotherapy. AACR – Advancing Precision Medicine Drug Development: Incorporation of Real-World Data and Other Novel Strategies. San Diego, CA. Jan 12, 2020.


11. Kim, R. Hereditary Cancer Syndrome Think Tank. Ontario Institute of Cancer Research, Feb 2020. Workshop.


12. Pugh, T. Detection and Monitoring of Cancer and Immune Systems in Pediatric Tumours. SickKids Distinguished Lecturer Series, March 2020.


13. Kim, R. Hereditary cancers, lesson from prevention and pedigrees. Prevention Genetics LLC, Wisconsin, Mar 2020.


14. Pugh, T. Molecular surveillance for LFS-associated cancers through cell-free DNA sequencing. DFCI Li-Fraumeni Syndrome Association Symposium. Holliston, MA, USA. (Virtual). Oct 2020.


15. Kim, R. Cancer Genetics, part II. Division of Clinical Genetics Grand Rounds. Hospital for Sick Children, Toronto, Ontario, Canada (Virtual). Sep 2020.


16. Bedard, PL. Targeting HER2 and DNA Repair. 2019 San Antonio Breast Cancer Symposium (SABCS), Dec 12, 2019. San Antonio, USA.


17. Bratman, S. HPV ctDNA quantification and characterization. EUROGIN 2019 Congress, Dec 2019. Monaco.


18. Kim, R. Familial Cancer Genetics, lessons from families and friends. University of Chicago, Oct 2019. Chicago, USA.


19. Siu LL. Precision medicine. Presidential Symposium at the Spanish Society of Medical Oncology (SEOM) Annual Congress, Oct 2019. Pamplona, Spain.


20. Bedard, PL. Building of a comprehensive clinical and molecular genomics database for patients with treatment-refractory cancers enrolled in clinical trials. ESMO 2019, Sep 29, 2019. Barcelona, Spain.


21. Kim, R. Hereditary cancer genetics, lessons from families and tough cases. National Human Genome Research Institute, Aug 2019. Bethesda, USA.


22. Bedard, PL. Discussant: Beyond ER: Unraveling CDK4/6 Resistance. ASCO Annual Meeting 2019, Jun 1, 2019. Chicago, USA.


23. Bedard, PL. How to set up a molecular tumour board. ASCO Annual Meeting 2019, Jun 1, 2019. Chicago, USA.


24. Pugh, T. Cell-free DNA sequencing as a molecular monitor for hereditary cancer. The Wyss Family ‘Think Tank’ on Genetic Predisposition to Primary CNS Cancer in Children, Adolescents and Young Adults, Jun 2019. Columbus, USA.


25. Kim, R. Hereditary cancer, leading precision cancer therapy. Not so rare when you think about it. Hospital for Sick Children, Jun 2019. Toronto, Canada.


26. Bedard, PL. The current landscape of biomarkers in community practice. COMET, May 14, 2019. Toronto, Canada.


27. Kim, R. Hereditary cancer genetics, the prodigal son returns. University of Washington Genetics Rounds, Apr 2019. Seattle, USA.


28. Kim, R. ctDNA: Circulating DNA, more than just NIPT. Hamilton Regional Clinical Genetics Conference, Mar 7, 2019. Hamilton, Canada.


29. Bratman, S. HPV biomarkers for assessment of treatment response. NRG Oncology Semiannual Meeting, Feb 2019. Phoenix, USA.


30. Siu, LL. The impact of monitoring tumors in clinical trials. Keynote Lecture at the European Association for Cancer Research (EACR) “Tracking Cancer Detection and Monitoring, from Diagnosis to Therapy” Conference, Feb 2019. Barcelona, Spain.


31. Siu, LL. Integrating Genomic Data into Treatment Decisions. Where We Stand in 2018? IOSI Teaching Conference. Bellinzona, Switzerland. 17 Oct 2018.


32. Pugh, TJ. Beyond mutations: New strategies for profiling cancer and immune systems during treatment. 2018 World Conference on Lung Cancer: Sino-Canada Dialogue on Lung Cancer Precision Medicine. Toronto, Ontario, Canada. September 2018.


33. Pugh, TJ. FAIR play with Big Data. Alex’s Lemonade Stand Crazy 8’s Initiative Workshop. Philadelphia, PA, USA. September 2018.


34. Pugh, TJ. Circulating tumor DNA as a molecular monitor for hereditary cancers. 4th International LFS Association Symposium. Toronto, Ontario, Canada. June 2018.


35. Siu, LL. Adaptive Trials and Targeted Agents (and Beyond). Personalized Health Conference. Zurich, Switzerland. 18-19 June 2018.


36. Pugh, TJ. Circulating tumor DNA as a molecular monitor for hereditary cancers. Toronto International Sarcoma Symposium. Toronto, Ontario, Canada. June 2018.


37. Siu, LL. Incorporating predictive biomarker development in first-in-class phase I trials – myth or must? LIF As We Know It in 2018. Barcelona, Spain. 28-29 May 2018.


38. Bedard, PL. Cancer Genomics Program. 2018 PM Research Retreat. Niagara-on-the-Lake, Ontario, Canada. 16 May 2018


39. Pugh, TJ. Simultaneous Analysis of Cancer Clones and Immune Microenvironments Through Single Cell RNA Sequencing. Association for Molecular Pathology Europe 2018. Rotterdam, Netherlands. May 2018.


40. Siu, LL. Decade of Precision Medicine: Reality or Myth? Keystone Conference. Stockholm, Sweden. 6-9 May 2018.


41. Pugh, TJ. Dissection of primary and cultured brain tumours using single cell sequencing. International Rhabdoid Tumour Meeting: Advancing Biology Based Therapies. Lake Louise, Alberta, Canada. April 2018.


42. Pugh, TJ. Application of Next-Generation Sequencing of Liquid Biopsies for Cancer Analysis. American College of Medical Genetics Annual Clinical Genetics Meeting. Charlotte, NC, USA. April 2018.


43. Siu, LL. Strategies, Biomarkers and Endpoints for Phase I and II Trials. JSMO/ASCO Young Oncologist Workshop. Tokyo, Japan. 7-11 Feb 2018.


44. Pugh, TJ. Genome analysis and data sharing informs timing of molecular events in pancreatic neuroendocrine tumour. Precision Medicine World Conference. Palo Alto, CA, USA. January 2018.


45. Pugh, TJ. Sharing heterogenous data across a heterogeneous team. StandUp2Cancer Scientific Summit. Los Angeles, CA, USA. January 2018.


46. Bedard, PL. Update on GENIE/Accelerating Precision Medicine. Princess Margaret Cancer Centre Conference. Toronto, Ontario, Canada. 19 Jan 2018


47. Siu, L. Precision Oncology - Lessons Learned and the Next Chapter. 2017 SWOG Annual Meeting, San Francisco, CA.


48. Siu, L. Clinical applications: drug access and design of genotype-specific trials. 2017 AACR, International Conference on Translational Cancer Medicine, Sao Paulo, Brazil.


49. Siu, L. Precision medicine in head and neck cancer: Myth or Reality? 2017 ESMO, Madrid, Spain.


50. Siu, L. Next generation cancer clinical trials. 2017 Cold Spring Harbor Laboratory. Cold Spring Harbor, New York.


51. Siu, L. ESMO, ASCO, NCCN Initiatives to measure clinical benefit or value and Biomarker driven research. 2017 International Clinical Trials Workshop by ASCO, Luoyang, China.


52. Siu, L. Clinical challenges with identifying / enriching populations for enrolment into clinical trials. 2017 OICR Biostatistics Workshop, Toronto, Ontario.


53. Siu, L. TF4CN - a transcontinental Canadian collaborative initiative. 2017 Terry Fox TFRI Ontario Node Symposium, Toronto, Ontario.


54. Bedard, P, Invited Speaker. Molecular Profiling of Advanced Solid Tumours. 2017 Genetic Grand Rounds. UHN/MSH, Toronto, ON, Canada.


55. Bedard, P. GenomeWeb story. Interviewer: Hal Costie, OICR. https://www.genomeweb.com/informatics/ontario-octane-genomic-data-sharing-study-kicks-gear . Ontario, Canada., Toronto, Canada.


56. Bedard, P, Invited Speaker. Update on the Cancer Genomics Program at Princess Margaret Cancer Centre. 2017 Cancer genomics and tumor immunotherapy symposium: A Clinical Perspective. Invited Speaker.


57. Bedard, P. Ontario wide targeted Nucleic Acid Evaluation (OCTANE). 2017 Monday OICR Talks.


58. Pugh, TJ, Invited Speaker. Data Sharing Initiatives in Canada: Highlighting Terry Fox Comprehensive Cancer Centre Consortium Network (TF4CN). 2017 Terry Fox Research Institute Ontario Node Annual Meeting. Toronto, ON, Canada


59. Pugh, TJ, Invited Speaker. Genome analysis and data sharing informs timing of molecular events in pancreatic neuroendocrine tumour. 2017 North American Neuroendocrine Tumour Society Annual Meeting, Philadelphia, PA, USA.


60. Pugh, TJ, Invited Speaker. Genome technologies to characterize cancer and immune systems in primary tumour tissues. 2017 NCIC Clinical Trials Group Annual Spring Meeting, Toronto, ON, Canada.


61. Pugh, TJ, Invited Speaker. Exploring the genomes of gastrointestinal and pancreatic NETs to find new targets and treatments. 2017 National Neuroendocrine Tumour Conference. Toronto, ON, Canada.


62. Pugh, TJ, Invited Speaker. Cancer: When good DNA goes bad, and what we can do about it. 2017 Medical Biophysics March Break Camp. Toronto, ON, Canada.


63. Pugh, TJ, Discussant. Panel Discussion: Towards Precision Medicine Initiatives. 2017 Genomic Medicine Canada 2017: A symposium to discuss precision medicine initiatives, Toronto, ON, Canada.


64. Rodriguez Freixinos V, Lheureux S, Mandilaras V, Clarke B, Dhani N, Mackay H, Butler M, Wang L, Siu LL, Kamel-Reid S, Stockley T, Bedard P, Oza AM. Integration of somatic molecular profiling for rare epithelial gynaecologic cancer patients. 2016 ASCO Annual Meeting. Abst 5509

Posters:

1. Malone E, Spreafico A, Jang R, Weinreb I, Jennings S, Siu LL, Hansen AR. Genomic Profiling and Matched Therapy for recurrent or metastatic malignant salivary gland tumors. European Society for Medical Oncology 2018 Congress. October 19-23, 2018. Munich, Germany. Poster 1078


2. Stockley T, Sukhai M, Kamel-Reid S, Van-Vooren S, Kanwar N. Identification of Somatic Tumor-Only Variants on 1120 Solid Tumor Cases through Intelligent Variant Filtration. The American Society of Human Genetics. October 19, 2017. Orlando, Florida, USA.


3. Garg S, Sukhai MA, Misyura M, Thomas M, Zhang T, Siu LL, Bedard PL, Stockley TL, Kamel-Reid S. Impact of TP53 status and molecular classification on molecular profiles in breast cancer subtypes. 2016 AACR Annual Meeting, April 16-20, 2016, New Orleans, LA.


4. Mandilaras V, Garg S, Burnier J, Karakasis K, Wang L, Mackay H, Dhani NC, Butler MO, Rodriguez-Freixinos V, Wilson MK, Martin-Lorente C, Ethier J, Bedard PL, Siu LL, Clarke B, Shaw PA, Stockley T, Oza AM, Lheureux S. P53 Functional Mutation Type in High Grade Serous Ovarian Cancer and Clinical Outcomes. 2016 ASCO Annual Meeting. Abst 5550


5. Stjepanovic N, Bedard PL, Oza A, Clarke B, Krzyzanowska M, Jang R, Dhani N, Leighl N, Gupta A, Elser C, McCuaig J, Aronson M, Holter S, Semotiuk K, Ahmed L, Wang L, Stockley T, Kamel-Reid S, Siu LL, Kim RH. Incidental germline findings identified in a somatic genomic sequencing program for advanced cancer patients. 2016 ASCO Annual Meeting. Abst 1532


6. Turner S, Alizadeh M, Leigh N, Shepherd FA, Zadeh G, Laperriere N, Millar BA, Bernstein M, Bedard PL, Chung C. Effect of Molecular Profile in Non-Small Cell Lung Carcinoma on the development of Brain Metastases. 2016 ASCO Annual Meeting. 2016 Jun. Abst 170342


7. Stjepanovic N, Wilson MK, Mandilaras V, Clarke B, Berman HK, Kim RH, Lheureux S, Randall-Armel S, McCuaig J, Volenik A, Demsky R, Chow H, Mysura M, Siu L, Bedard PL, Kamel-Reid S, Stockley T, Oza A. Germline and somatic multi-gene sequencing in patients with advanced high grade serous ovarian cancer and triple negative breast cancer. 2016 ESMO Annual Symposium. Abst 1547P


8. Stjepanovic N, Garg S, Berman HK, Warr D, Amir E, Cescon D, Elser C, Wang L, Kamel-Reid S, Siu LL, Bedard PL, Stockley T. Impact of TP53 functional mutation type on clinical outcomes of advanced breast cancer patients. 2016 San Antonio Breast Cancer Symposium (SABCS). Abst 923


9. Stjepanovic N, Kim RH, Wilson MK, Mandilaras V, Berman HK, Warr D, Amir E, Cescon D, Elser C, Randall-Armel S, McCuaig J, Volenik A, Demsky R, Chow H, Mysura M, Wang L, Oza A, Kamel-Reid S, Stockley T, Bedard PL. Clinical outcomes of patients with advanced triple negative breast cancer with germline and somatic variants in homologous recombination genes. 2016 San Antonio Breast Cancer Symposium (SABCS). Abst 1128